Definitive Healthcare Corp DH.OQ DH.O is expected to show a fall in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The Framingham Massachusetts-based company is expected to report a 11.5% decrease in revenue to $56.183 million from $63.48 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Definitive Healthcare Corp is for earnings of 2 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 8 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Definitive Healthcare Corp is $4.75, above its last closing price of $2.77.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.07
0.07
0.08
Beat
12.9
Sep. 30 2024
0.08
0.08
0.10
Beat
25.5
Jun. 30 2024
0.09
0.09
0.09
Met
3.7
Mar. 31 2024
0.08
0.08
0.08
Met
-1.9
Dec. 31 2023
0.08
0.08
0.07
Missed
-8.4
Sep. 30 2023
0.07
0.06
0.09
Beat
49.1
Jun. 30 2023
0.06
0.06
0.08
Beat
44.6
Mar. 31 2023
0.05
0.04
0.06
Beat
35
This summary was machine generated May 6 at 20:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)